Author Archives: Denise Bell
Rep. Burgess Owens Spends a Day in the BioHive
Utah life sciences companies took center stage September 2, as U.S. Representative Burgess Owens (R-UT) toured Canyon Labs, Ultradent (Canyon Labs’ parent company), Ortho Development and Xenter – all innovative leaders in advancing medical technologies that improve patient care and provide jobs for hundreds of Utahns. BioUtah helped to facilitate the BioHive day. “Utah is […]
Senator Mike Lee Spends a Day in the BioHive
U.S. Senator Mike Lee (R-UT) on August 15 spent the day connecting with Utah’s life sciences community, known as the BioHive, touring facilities at BD, IONIQ Sciences, SEEK Labs and Carterra. His schedule also included a tour of Altitude Lab in the University of Utah’s Research Park where he led a roundtable discussion with nearly […]
Sumitomo Pharma Oncology Receives Orphan Drug Designation for DSP-5336, an Investigational Menin and Mixed-Lineage Leukemia Binding Protein for Treatment of Acute Myeloid Leukemia
Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics has announced the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation for DSP-5336, an investigational small molecule inhibitor against the binding of menin and mixed-lineage leukemia (MLL) protein, for the treatment of acute myeloid leukemia (AML). “We are pleased to have […]
Senate Democrats Push Drug Pricing, Tax, Climate Package
Sen. Joe Manchin (D-W. Va.) on Wednesday said he had signed off on a revised “Build Back Better” plan, renamed the “Inflation Reduction Act of 2022,” which includes sweeping drug price controls along with tax increases and billions for climate and energy spending. The bill’s drug pricing provisions would allow Medicare to negotiate drug prices […]
BioUtah Joins State BIOs in Opposing Drug Price Controls
Senate Democrats are inching closer to a vote on a revived “Build Back Better” package, largely focused on drug pricing. The package would give Medicare the authority to negotiate drug prices and impose inflation rebates. The negotiation process, in practice, would function more like government price controls since drug manufacturers deemed non-compliant with the requirements […]
Sumitomo Pharma Oncology Receives Orphan Drug Designation for TP-3654, an Investigational Oral Inhibitor of PIM Kinases for the Treatment of Myelofibrosis
Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, recently announced that the FDA granted Orphan Drug Designation for TP-3654, the company’s proprietary investigational oral inhibitor of PIM kinases, for the treatment of myelofibrosis. “This designation is an important milestone in the development of TP-3654 and highlights the need for potential new treatment […]
Sumitomo Pharma Oncology, Inc. Pursues Research and Discovery with Persistence – Featured in Pharma Tech Outlook
Sumitomo Pharma Oncology, Inc. (SMP Oncology) and Steve Warner, Ph.D., Senior Vice President and Head of US Research at SMP Oncology, were recently featured in a Pharma Tech Outlook. In “Sumitomo Pharma Oncology: Discovering Immunotherapy Agents with Persistence,” Dr. Warner discusses SMP Oncology’s ongoing work in immunotherapy drug discovery, highlighting the progress with the Company’s […]
Invest Lithuania
BioUtah has established a partnership with Invest Lithuania, an arm of the Lithuanian government focused on developing life sciences in their country. The life sciences sector in Lithuania is regarded as one of the most highly developed in Central and Eastern Europe (CEE). The sector is driven by innovation and aims to become Europe’s next […]
BioHive Takes the Stage at One Utah Summit
The BioHive community was featured prominently at the One Utah Summit held on May 10 at the Grand America Hotel in Salt Lake City. Speakers from the life sciences industry addressed the crowd on topics ranging from job creation and talent development to life-saving innovation and drug discovery. Tom Polen, CEO of BD, and Rob […]
Recursion Co-Founder and CEO, Chris Gibson, Awarded Governor’s Medal for Science and Technology
Recursion Co-founder and CEO, Chris Gibson, Ph.D., was honored at the One Utah Summit on May 10, receiving the Governor’s Medal for Science and Technology. Gov. Spencer Cox presented the award during the summit’s special recognition ceremony. The prestigious award commends the distinguished service, significant achievement, and positive economic impact of individuals to the state […]
Healthcare Priorities of President Biden’s FY23 Budget
On Monday, March 28, President Biden announced his budget for FY23, a $5.8 trillion proposal that reflects the administration’s funding priorities, many of which were drawn from the initial Build Back Better package. Congress is not required to adopt any or all of the president’s budget. However, each year, the president’s budget proposal serves as […]
MDUFA V Agreement Reached
The FDA and representatives from the medical device industry have reached an agreement on proposed recommendations for MDUFA V. On March 22, FDA sent the commitment letter to Congress. Under the new agreement, the FDA would be authorized to collect at least $1.78 billion in user fees over five years. FDA could receive additional funding […]